Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer

Cabazitaxel provided a survival advantage compared with mitoxantrone in patients with castration-resistant prostate cancer refractory to docetaxel. Grade 3 to 4 (G3–4) neutropenia and febrile neutropenia were relatively frequent in the registrative XRP6258 Plus Prednisone Compared to Mitoxantrone Pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lorenzo, Giuseppe, Bracarda, Sergio, Gasparro, Donatello, Gernone, Angela, Messina, Caterina, Zagonel, Vittorina, Puglia, Livio, Bosso, Davide, Dondi, Davide, Sonpavde, Guru, Lucarelli, Giuseppe, De Placido, Sabino, Buonerba, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718232/
https://www.ncbi.nlm.nih.gov/pubmed/26765406
http://dx.doi.org/10.1097/MD.0000000000002299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718232/
https://www.ncbi.nlm.nih.gov/pubmed/26765406
http://dx.doi.org/10.1097/MD.0000000000002299

Ejemplares similares